Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous and Subcutaneous): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
Immunoglobulin Market Overview:
The global immunoglobulin was valued at $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs) or antibodies are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and are specific in their action. They are obtained from blood through the process of fractionation and are purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously for the treatment of various deficiencies.
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the immunoglobulin market. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the market growth. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin is anticipated to hamper the market growth.
On the contrary, significant investment in healthcare sector is predicted to create lucrative opportunities in the near future.
The global immunoglobulin market is characterized based on application, product type, mode of delivery, and region. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is classified into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Immunoglobulin Market:
By Application
The global immunoglobulin was valued at $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs) or antibodies are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and are specific in their action. They are obtained from blood through the process of fractionation and are purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously for the treatment of various deficiencies.
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the immunoglobulin market. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the market growth. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin is anticipated to hamper the market growth.
On the contrary, significant investment in healthcare sector is predicted to create lucrative opportunities in the near future.
The global immunoglobulin market is characterized based on application, product type, mode of delivery, and region. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is classified into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Immunoglobulin Market:
- The study provides an in-depth analysis of the immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided.
- A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
- An extensive analysis of the key segments of the industry helps to understand the trends in the immunoglobulin market globally.
- Key players and their strategies are provided to understand the competitive outlook of the industry.
By Application
- Hypogammaglobulinemia
- Chronic Inflammatory Demyelinating Polyneuropathy
- Primary Immunodeficiency Disease
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain-Barre Syndrome
- Others
- IgG
- IgA
- IgM
- IgE
- IgD
- Intravenous
- 5% Concentration
- 10% Concentration
- Others
- Sucutaneous
- 16.5% Concentration
- 20% Concentration
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- France
- Germany
- Italy
- France
- Austria
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Saudi Arabia
- Brazil
- Turkey
- Argentina
- Rest of LAMEA
- Baxter international Inc.
- CSL Ltd.
- Grifols S.A.
- Octapharma AG
- Kedrion Biopharma Inc.
- LFB group
- Biotest AG
- China Biologics Products, Inc.
- Shire Plc.(Baxalta)
- Bayer AG
- Hualan Biological Engineering Inc.
- Omrix Biopharmaceuticals Ltd.
- Behring GmbH
- Shanghai RAAS Blood Products Co., Ltd.
- Option Care Enterprises, Inc.
- ADMA Biologics, Inc.
- BioScrip, Inc
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Market share analysis, 2017
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of immunodeficiency diseases
3.5.1.2. Increase in adoption of immunoglobulin
3.5.1.3. Increase in incidence of bleeding disorders
3.5.1.4. Surge in geriatric population
3.5.2. Restraints
3.5.2.1. Stringent government regulations
3.5.2.2. High cost of therapy
3.5.3. Opportunities
3.5.3.1. Opportunities in emerging economies
3.5.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. HYPOGAMMAGLOBULINEMIA
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Idiopathic thrombocytopenic purpura
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11. Others
4.11.1. Market size and forecast
CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
5.1. Overview
5.1.1. IGG
5.1.2. Key market trends
5.1.3. Clinical interpretations
5.1.4. IGA
5.1.5. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGM
5.1.8. Key Market Trends
5.1.9. Clinical interpretation
5.1.10. IGE
5.1.11. Key Market Trend
5.1.12. Clinical interpretation
5.1.13. IGD
5.1.14. Key Market Trends
5.1.15. Clinical interpretation
CHAPTER 6: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY
6.1. Overview
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Key Market Trends
6.2.2. Market size and forecast
6.2.2.1. 5% concentration
6.2.3. Market size and forecast
6.2.3.1. 10% Concentration
6.2.4. Market size and forecast
6.2.4.1. Other Concentrations
6.2.5. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Key Market Trends
6.3.2. Market size and forecast
6.3.2.1. 5% Concentration
6.3.3. Market size and forecast
6.3.3.1. 16.5% Concentration
6.3.4. Market size and forecast
6.3.4.1. 20% Concentration
6.3.5. Market size and forecast
6.3.5.1. Other Concentration
6.3.6. Market size and forecast
CHAPTER 7: IMMUNOGLOBULIN MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. North America market size & forecast, by country
7.2.3. North America market size & forecast, by application
7.2.4. North America market size & forecast, by mode of delivery
7.2.4.1. U.S. market size & forecast
7.2.4.2. Canada market size & forecast
7.2.4.3. Mexico market size & forecast
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Europe market size & forecast for immunoglobulin market, by country
7.3.3. Europe market size & forecast, by application
7.3.4. Europe market size & forecast, by mode of delivery
7.3.4.1. Germany market size & forecast
7.3.4.2. France market size & forecast
7.3.4.3. UK market size & forecast
7.3.4.4. Italy market size & forecast
7.3.4.5. Spain market size & forecast
7.3.4.6. Russia market size & forecast
7.3.4.7. Rest of Europe market size & forecast
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size & forecast, by country
7.4.3. Asia-Pacific market size & forecast, by application
7.4.4. Asia-Pacific market size & forecast, by mode of delivery
7.4.4.1. Japan market size & forecast
7.4.4.2. China market size & forecast
7.4.4.3. India market size & forecast
7.4.4.4. Australia market size & forecast
7.4.4.5. South Korea market size & forecast
7.4.4.6. Taiwan market size & forecast
7.4.4.7. Rest of Asia-Pacific market size & forecast
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. LAMEA market size & forecast, by country
7.5.3. LAMEA market size & forecast, by application
7.5.4. LAMEA market size & forecast, by mode of delivery
7.5.4.1. Brazil market size & forecast
7.5.4.2. South Africa market size & forecast
7.5.4.3. Saudi Arabia market size & forecast
7.5.4.4. Argentina market size & forecast
7.5.4.5. Rest of LAMEA market size & forecast
CHAPTER 8: COMPANY PROFILES
8.1. Baxter International Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Biotest AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. CSL Limited
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Grifols S.A.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. LFB SA (LFB Biotechnologies SAS)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Octapharma AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Bayer AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. Kedrion Biopharma Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Shire Plc.(Baxalta)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. China Biologic Products, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Market share analysis, 2017
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of immunodeficiency diseases
3.5.1.2. Increase in adoption of immunoglobulin
3.5.1.3. Increase in incidence of bleeding disorders
3.5.1.4. Surge in geriatric population
3.5.2. Restraints
3.5.2.1. Stringent government regulations
3.5.2.2. High cost of therapy
3.5.3. Opportunities
3.5.3.1. Opportunities in emerging economies
3.5.3.2. Development of cost-effective therapeutics through large-scale production
CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. HYPOGAMMAGLOBULINEMIA
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Idiopathic thrombocytopenic purpura
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11. Others
4.11.1. Market size and forecast
CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
5.1. Overview
5.1.1. IGG
5.1.2. Key market trends
5.1.3. Clinical interpretations
5.1.4. IGA
5.1.5. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGM
5.1.8. Key Market Trends
5.1.9. Clinical interpretation
5.1.10. IGE
5.1.11. Key Market Trend
5.1.12. Clinical interpretation
5.1.13. IGD
5.1.14. Key Market Trends
5.1.15. Clinical interpretation
CHAPTER 6: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY
6.1. Overview
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Key Market Trends
6.2.2. Market size and forecast
6.2.2.1. 5% concentration
6.2.3. Market size and forecast
6.2.3.1. 10% Concentration
6.2.4. Market size and forecast
6.2.4.1. Other Concentrations
6.2.5. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Key Market Trends
6.3.2. Market size and forecast
6.3.2.1. 5% Concentration
6.3.3. Market size and forecast
6.3.3.1. 16.5% Concentration
6.3.4. Market size and forecast
6.3.4.1. 20% Concentration
6.3.5. Market size and forecast
6.3.5.1. Other Concentration
6.3.6. Market size and forecast
CHAPTER 7: IMMUNOGLOBULIN MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. North America market size & forecast, by country
7.2.3. North America market size & forecast, by application
7.2.4. North America market size & forecast, by mode of delivery
7.2.4.1. U.S. market size & forecast
7.2.4.2. Canada market size & forecast
7.2.4.3. Mexico market size & forecast
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Europe market size & forecast for immunoglobulin market, by country
7.3.3. Europe market size & forecast, by application
7.3.4. Europe market size & forecast, by mode of delivery
7.3.4.1. Germany market size & forecast
7.3.4.2. France market size & forecast
7.3.4.3. UK market size & forecast
7.3.4.4. Italy market size & forecast
7.3.4.5. Spain market size & forecast
7.3.4.6. Russia market size & forecast
7.3.4.7. Rest of Europe market size & forecast
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size & forecast, by country
7.4.3. Asia-Pacific market size & forecast, by application
7.4.4. Asia-Pacific market size & forecast, by mode of delivery
7.4.4.1. Japan market size & forecast
7.4.4.2. China market size & forecast
7.4.4.3. India market size & forecast
7.4.4.4. Australia market size & forecast
7.4.4.5. South Korea market size & forecast
7.4.4.6. Taiwan market size & forecast
7.4.4.7. Rest of Asia-Pacific market size & forecast
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. LAMEA market size & forecast, by country
7.5.3. LAMEA market size & forecast, by application
7.5.4. LAMEA market size & forecast, by mode of delivery
7.5.4.1. Brazil market size & forecast
7.5.4.2. South Africa market size & forecast
7.5.4.3. Saudi Arabia market size & forecast
7.5.4.4. Argentina market size & forecast
7.5.4.5. Rest of LAMEA market size & forecast
CHAPTER 8: COMPANY PROFILES
8.1. Baxter International Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Biotest AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. CSL Limited
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Grifols S.A.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. LFB SA (LFB Biotechnologies SAS)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Octapharma AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Bayer AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. Kedrion Biopharma Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Shire Plc.(Baxalta)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. China Biologic Products, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 02. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAM)
TABLE 03. GLOBAL IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 ($MILLION)
TABLE 04. GLOBAL IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 ($MILLION)
TABLE 05. GLOBAL IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 (KILOGRAMS)
TABLE 06. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA BY REGION, 20172025 ($MILLION)
TABLE 07. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA BY REGION, 20172025 (KILOGRAMS)
TABLE 08. GLOBAL IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 ($MILLION)
TABLE 09. GLOBAL IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 (KILOGRAMS)
TABLE 10. GLOBAL IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 ($MILLION)
TABLE 11. GLOBAL IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 (KILOGRAMS)
TABLE 12. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 ($MILLION)
TABLE 13. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 (KILOGRAMS)
TABLE 14. GLOBAL IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 ($MILLION)
TABLE 15. GLOBAL IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 (KILOGRAMS)
TABLE 16. GLOBAL IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 ($MILLION)
TABLE 17. GLOBAL IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 (KILOGRAMS)
TABLE 18. GLOBAL IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME, BY REGION, 20172025 ($MILLION)
TABLE 19. GLOBAL IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME), BY REGION, 20172025 (KILOGRAMS)
TABLE 20. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 21. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 (KILOGRAMS)
TABLE 22. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 23. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 (KILOGRAMS)
TABLE 24. IMMUNOGLOBULIN MARKET, FOR INTRAVENOUS, BY REGION, 20172025 ($MILLION)
TABLE 25. IMMUNOGLOBULIN MARKET, FOR INTRAVENOUS, BY REGION, 20172025 (KILOGRAMS)
TABLE 26. IMMUNOGLOBULIN MARKET, FOR 5% CONCENTRATION, BY REGION, 20172025 ($MILLION)
TABLE 27. IMMUNOGLOBULIN MARKET, FOR 10% CONCENTRATION, 20172025 ($MILLION)
TABLE 28. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHER CONCENTRATIONS, 20172025 ($MILLION)
TABLE 29. IMMUNOGLOBULIN MARKET, FOR SUBCUTANEOUS MODE OF DELIVERY, BY REGION, 20172025 ($MILLION)
TABLE 30. IMMUNOGLOBULIN MARKET, FOR SUBCUTANEOUS MODE OF DELIVERY, BY REGION, 20172025 (KILOGRAMS)
TABLE 31. GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 20172025 ($MILLION)
TABLE 32. GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 20172025 (KILOGRAMS)
TABLE 33. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 34. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)
TABLE 35. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 36. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TARGET AREA, 20172025 ($MILLION)
TABLE 37. EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 38. EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 39. EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 40. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 41. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 42. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 43. LAMEA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 44. LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 45. LAMEA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 46. BAXTER: COMPANY SNAPSHOT
TABLE 47. BAXTER: OPERATING SEGMENTS
TABLE 48. BAXTER: PRODUCT PORTFOLIO
TABLE 49. BIOTEST: COMPANY SNAPSHOT
TABLE 50. BIOTEST: OPERATING SEGMENTS
TABLE 51. BIOTEST: OPERATING SEGMENT
TABLE 52. CSL: COMPANY SNAPSHOT
TABLE 53. CSL: PRODUCT SEGMENTS
TABLE 54. CSL: PRODUCT PORTFOLIO
TABLE 55. GRIFOLS: COMPANY SNAPSHOT
TABLE 56. GRIFOLS: OPERATING SEGMENTS
TABLE 57. GRIFOLS: PRODUCT PORTFOLIO
TABLE 58. LFB: COMPANY SNAPSHOT
TABLE 59. LFB: PRODUCT SEGMENTS
TABLE 60. LFB: PRODUCT PORTFOLIO
TABLE 61. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 62. OCTAPHARMA: PRODUCT SEGMENTS
TABLE 63. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 64. BAYER: COMPANY SNAPSHOT
TABLE 65. BAYER: OPERATING SEGMENTS
TABLE 66. KEDRION: COMPANY SNAPSHOT
TABLE 67. KEDRION: PRODUCT PORTFOLIO
TABLE 68. SHIRE: COMPANY SNAPSHOT
TABLE 69. SHIRE: PRODUCT PORTFOLIO
TABLE 70. CHINA BIOLOGIC COMPANY SNAPSHOT
TABLE 71. CHINA BIOLOGIC PRODUCT PORTFOLIO
TABLE 01. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 02. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 (KILOGRAM)
TABLE 03. GLOBAL IMMUNOGLOBULIN MARKET, FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 20172025 ($MILLION)
TABLE 04. GLOBAL IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 ($MILLION)
TABLE 05. GLOBAL IMMUNOGLOBULIN MARKET, FOR CIPD, BY REGION, 20172025 (KILOGRAMS)
TABLE 06. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA BY REGION, 20172025 ($MILLION)
TABLE 07. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA BY REGION, 20172025 (KILOGRAMS)
TABLE 08. GLOBAL IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 ($MILLION)
TABLE 09. GLOBAL IMMUNOGLOBULIN MARKET, FOR MYASTHENIA GRAVIS (MG), BY REGION, 20172025 (KILOGRAMS)
TABLE 10. GLOBAL IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 ($MILLION)
TABLE 11. GLOBAL IMMUNOGLOBULIN MARKET, FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 20172025 (KILOGRAMS)
TABLE 12. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 ($MILLION)
TABLE 13. GLOBAL IMMUNOGLOBULIN MARKET, FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 20172025 (KILOGRAMS)
TABLE 14. GLOBAL IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 ($MILLION)
TABLE 15. GLOBAL IMMUNOGLOBULIN MARKET, FOR INFLAMMATORY MYOPATHY, BY REGION, 20172025 (KILOGRAMS)
TABLE 16. GLOBAL IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 ($MILLION)
TABLE 17. GLOBAL IMMUNOGLOBULIN MARKET, FOR SPECIFIC ANTIBODY DEFICIENCY (SAD), BY REGION, 20172025 (KILOGRAMS)
TABLE 18. GLOBAL IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME, BY REGION, 20172025 ($MILLION)
TABLE 19. GLOBAL IMMUNOGLOBULIN MARKET, FOR GUILLAIN-BARRE SYNDROME), BY REGION, 20172025 (KILOGRAMS)
TABLE 20. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 21. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHERS, BY REGION, 20172025 (KILOGRAMS)
TABLE 22. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 23. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 (KILOGRAMS)
TABLE 24. IMMUNOGLOBULIN MARKET, FOR INTRAVENOUS, BY REGION, 20172025 ($MILLION)
TABLE 25. IMMUNOGLOBULIN MARKET, FOR INTRAVENOUS, BY REGION, 20172025 (KILOGRAMS)
TABLE 26. IMMUNOGLOBULIN MARKET, FOR 5% CONCENTRATION, BY REGION, 20172025 ($MILLION)
TABLE 27. IMMUNOGLOBULIN MARKET, FOR 10% CONCENTRATION, 20172025 ($MILLION)
TABLE 28. GLOBAL IMMUNOGLOBULIN MARKET, FOR OTHER CONCENTRATIONS, 20172025 ($MILLION)
TABLE 29. IMMUNOGLOBULIN MARKET, FOR SUBCUTANEOUS MODE OF DELIVERY, BY REGION, 20172025 ($MILLION)
TABLE 30. IMMUNOGLOBULIN MARKET, FOR SUBCUTANEOUS MODE OF DELIVERY, BY REGION, 20172025 (KILOGRAMS)
TABLE 31. GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 20172025 ($MILLION)
TABLE 32. GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 20172025 (KILOGRAMS)
TABLE 33. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 34. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 (KILOGRAMS)
TABLE 35. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 36. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TARGET AREA, 20172025 ($MILLION)
TABLE 37. EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 38. EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 39. EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 40. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 41. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 42. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 43. LAMEA IMMUNOGLOBULIN MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 44. LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 45. LAMEA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 20172025 ($MILLION)
TABLE 46. BAXTER: COMPANY SNAPSHOT
TABLE 47. BAXTER: OPERATING SEGMENTS
TABLE 48. BAXTER: PRODUCT PORTFOLIO
TABLE 49. BIOTEST: COMPANY SNAPSHOT
TABLE 50. BIOTEST: OPERATING SEGMENTS
TABLE 51. BIOTEST: OPERATING SEGMENT
TABLE 52. CSL: COMPANY SNAPSHOT
TABLE 53. CSL: PRODUCT SEGMENTS
TABLE 54. CSL: PRODUCT PORTFOLIO
TABLE 55. GRIFOLS: COMPANY SNAPSHOT
TABLE 56. GRIFOLS: OPERATING SEGMENTS
TABLE 57. GRIFOLS: PRODUCT PORTFOLIO
TABLE 58. LFB: COMPANY SNAPSHOT
TABLE 59. LFB: PRODUCT SEGMENTS
TABLE 60. LFB: PRODUCT PORTFOLIO
TABLE 61. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 62. OCTAPHARMA: PRODUCT SEGMENTS
TABLE 63. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 64. BAYER: COMPANY SNAPSHOT
TABLE 65. BAYER: OPERATING SEGMENTS
TABLE 66. KEDRION: COMPANY SNAPSHOT
TABLE 67. KEDRION: PRODUCT PORTFOLIO
TABLE 68. SHIRE: COMPANY SNAPSHOT
TABLE 69. SHIRE: PRODUCT PORTFOLIO
TABLE 70. CHINA BIOLOGIC COMPANY SNAPSHOT
TABLE 71. CHINA BIOLOGIC PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. IMMUNOGLOBULIN MARKET SEGMENTATION
FIGURE 02. TOP WINNING STRATEGIES, BY YEAR, 2015-2018
FIGURE 03. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018 (%)
FIGURE 04. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. HIGH BARGAINING POWER OF BUYERS
FIGURE 07. HIGH THREAT OF SUBSTITUTION
FIGURE 08. HIGH THREAT OF NEW ENTRANTS
FIGURE 09. HIGH COMPETITIVE RIVALRY
FIGURE 10. MARKET SHARE ANALYSIS, 2017
FIGURE 11. GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 01. U.S. IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 02. CANADA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 03. MEXICO IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 04. GERMANY IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 05. FRANCE IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 06. UK IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 07. ITALY IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 08. SPAIN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 09. RUSSIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 10. REST OF EUROPE IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 11. JAPAN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 12. CHINA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 13. INDIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 14. AUSTRALIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 15. AUSTRALIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 16. TAIWAN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 17. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 18. BRAZIL IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 19. SOUTH AFRICA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 20. SAUDI ARABIA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)
FIGURE 21. ARGENTINA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)
FIGURE 22. REST OF LAMEA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)
FIGURE 23. BAXTER: NET SALES, 20152017 ($MILLION)
FIGURE 24. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. BIOTEST: NET SALES, 20152017 ($MILLION)
FIGURE 27. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. BIOTEST: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. CSL: NET SALES, 20152017 ($MILLION)
FIGURE 30. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 31. CSL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 32. GRIFOLS: NET SALES, 20152017 ($MILLION)
FIGURE 33. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34. GRIFOLS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 35. LFB: NET SALES, 20142016 ($MILLION)
FIGURE 36. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 37. LFB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. OCTAPHARMA: NET SALES, 20152017 ($MILLION)
FIGURE 39. BAYER: NET SALES, 20152017 ($MILLION)
FIGURE 40. BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. BAYER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. KEDRION: NET SALES, 20152017 ($MILLION)
FIGURE 43. KEDRION: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 44. SHIRE: NET SALES, 20152017 ($MILLION)
FIGURE 45. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 46. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 47. CHINA BIOLOGIC NET SALES, 20152017 ($MILLION)
FIGURE 01. IMMUNOGLOBULIN MARKET SEGMENTATION
FIGURE 02. TOP WINNING STRATEGIES, BY YEAR, 2015-2018
FIGURE 03. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018 (%)
FIGURE 04. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. HIGH BARGAINING POWER OF BUYERS
FIGURE 07. HIGH THREAT OF SUBSTITUTION
FIGURE 08. HIGH THREAT OF NEW ENTRANTS
FIGURE 09. HIGH COMPETITIVE RIVALRY
FIGURE 10. MARKET SHARE ANALYSIS, 2017
FIGURE 11. GLOBAL IMMUNOGLOBULIN MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 01. U.S. IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 02. CANADA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 03. MEXICO IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 04. GERMANY IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 05. FRANCE IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 06. UK IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 07. ITALY IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 08. SPAIN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 09. RUSSIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 10. REST OF EUROPE IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 11. JAPAN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 12. CHINA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 13. INDIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 14. AUSTRALIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 15. AUSTRALIA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 16. TAIWAN IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 17. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 18. BRAZIL IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 19. SOUTH AFRICA IMMUNOGLOBULIN MARKET, 2017-2025 ($ MILLION)
FIGURE 20. SAUDI ARABIA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)
FIGURE 21. ARGENTINA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)
FIGURE 22. REST OF LAMEA IMMUNOGLOBULIN MARKET, 20172025 ($MILLION)
FIGURE 23. BAXTER: NET SALES, 20152017 ($MILLION)
FIGURE 24. BAXTER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. BIOTEST: NET SALES, 20152017 ($MILLION)
FIGURE 27. BIOTEST: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. BIOTEST: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. CSL: NET SALES, 20152017 ($MILLION)
FIGURE 30. CSL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 31. CSL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 32. GRIFOLS: NET SALES, 20152017 ($MILLION)
FIGURE 33. GRIFOLS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34. GRIFOLS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 35. LFB: NET SALES, 20142016 ($MILLION)
FIGURE 36. LFB: REVENUE SHARE BY PRODUCT SEGMENT, 2016 (%)
FIGURE 37. LFB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. OCTAPHARMA: NET SALES, 20152017 ($MILLION)
FIGURE 39. BAYER: NET SALES, 20152017 ($MILLION)
FIGURE 40. BAYER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. BAYER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. KEDRION: NET SALES, 20152017 ($MILLION)
FIGURE 43. KEDRION: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 44. SHIRE: NET SALES, 20152017 ($MILLION)
FIGURE 45. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 46. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 47. CHINA BIOLOGIC NET SALES, 20152017 ($MILLION)
